Airway Therapeutics secures $1.9 million NIH grant to advance late-stage clinical trials for bronchopulmonary dysplasia prevention
Executive summary: Airway Therapeutics was awarded a $1.9 million grant from the NIH to fund its ongoing Phase 2b/3 clinical study of Zelpultide alfa. The grant provides non-dilutive capital to advance a late-stage clinical program for bronchopulmonary dysplasia, reducing the company's immediate need for equity financing.
Who is involved: Airway Therapeutics and the National Institutes of Health (NIH).
Likely next: Execution of Phase 2b/3 clinical trial milestones and continued data accumulation for regulatory submission.
Airway Therapeutics has secured a $1.9 million grant from the National Institutes of Health to support the Phase 2b/3 clinical trial of Zelpultide alfa, its investigational therapy aimed at preventing bronchopulmonary dysplasia in preterm infants. The award follows previously reported Phase 1b data that demonstrated the drug’s safety and tolerability, allowing the company to move into a larger efficacy study without issuing additional equity. In parallel, the company recently closed a $50 million financing round, which provides further resources for manufacturing, trial operations and regulatory preparation. The NIH funding is non‑dilutive, meaning it does not increase shareholder ownership pressure, and it helps de‑risk the late‑stage development of a product that addresses a significant unmet need in neonatal care. By advancing Zelpultide alfa through a pivotal trial, Airway Therapeutics positions itself to potentially submit a biologics license application in the coming years, should the study meet its endpoints. The combined public and private capital inflows suggest the company is well‑placed to continue clinical progress, though the ultimate commercial outlook will depend on the trial’s results and subsequent regulatory decisions.
What's next — scenarios
Base Case: Successful Phase 2b/3 progression (60%)
The company continues to meet clinical milestones, potentially attracting larger pharmaceutical partners for licensing.
- Positive Phase 2b interim data
- Continued NIH milestone fulfillment
Upside: Accelerated FDA pathway (15%)
Successful results lead to breakthrough therapy designation or expedited review processes.
- FDA grant of Fast Track status
- Exceptional efficacy data in Phase 2b
Downside: Clinical trial delay or failure (25%)
Failure to meet primary endpoints in Phase 2b/3 would necessitate a pivot or asset liquidation.
- Failure to meet primary efficacy endpoints
- Safety signal surfacing in late-stage patients
What to watch
- Phase 2b/3 clinical trial enrollment milestones
- Publication of interim safety/efficacy data from Zelpultide alfa trials
- Any additional federal grant awards or private funding rounds
Timeline
- — Airway Therapeutics receives $1.9M NIH grant for Zelpultide alfa Phase 2b/3 study (PR Newswire)
- — Airway Therapeutics closes $50M funding round for Zelpultide Alfa development (PR Newswire)
Analysis — what this means
Likely next events
- Phase 2b/3 clinical trial progress updates (ongoing)
Sectors affected
- biotechnology
- neonatal healthcare
- pharmaceutical research
Regulatory implications
- NIH funding mandates adherence to federal research protocols
- Phase 2b/3 data will be critical for eventual FDA Investigational New Drug (IND) or New Drug Application (NDA) updates
Historical parallels
- Tempo Therapeutics awarded $2.25M NIH grant for wound healing (Sept 2026)
- Inomagen Therapeutics awarded up to $2.9M NIH grant for gene therapy (Sept 2026)
Key entities
Sources
- Airway Therapeutics receives $1.9M NIH grant for Zelpultide alfa Phase 2b/3 study — PR Newswire
- Airway Therapeutics closes $50M funding round for Zelpultide Alfa development — PR Newswire